查詢結果分析
來源資料
相關文獻
- 抗凝藥: 血小板環腺苷酸磷酸二酯酶及前列凝素A [feaf]合成酶抑制劑
- Lipopolysaccharide-stimulated Leukocytes Contribute to Platelet Aggregative Dysfunction, Which is Attenuated by Catalase in Rats
- 有關血小板醣蛋白Ⅱb/Ⅲa接受體拮抗劑的最新發展
- 一氧化氮(NO)在中樞心臟血管調控所扮演的角色
- Safety and Efficacy of the Platelet Glycoprotein IIb/IIIa Inhibitor Abciximab in Chinese Patients Undergoing High-Risk Angioplasty
- 維生素B6可減緩胰島素治療糖尿病大白鼠血管併發症
- 如何面對急性冠狀動脈性心臟病症候群(Acute Coronary Syndrome)--從病理生理機轉看抗血小板及抗凝血藥物的原理及角色
- Ticlopidine引起之嗜中性白血球缺乏
- 血小板抑制劑治療的藥理機轉
- 3,4-Dimethyl-2-phenylmethylfuro[2,3-c] pyrazole-5-carboxylic Acid, an Inhibitor of Platelet Aggregation
頁籤選單縮合
題名 | 抗凝藥: 血小板環腺苷酸磷酸二酯酶及前列凝素A [feaf]合成酶抑制劑=Anti-Aggregation Agents: Inhibitors of Platelet cAMP Phosphodiesterase and TXA2 Synthase |
---|---|
作者 | 李安榮; | 書刊名 | 醫學研究 |
卷期 | 13:1 1992.07[民81.07] |
頁次 | 頁1-16 |
分類號 | 418.2321 |
關鍵詞 | 合成酶; 血小板; 抗凝藥; 抑制劑; 前列凝素; 環腺苷酸; 磷酸二酯酶; |
語文 | 中文(Chinese) |
中文摘要 | 血小板活化凝集易形成血栓及栓塞,並為造成心絞痛、心肌梗塞及中風的原因。活化之血小板促使快速形成凝血酶,後者又會強力活化循環之血小板,致使反復刺激血小板凝集,形成血栓或導致動脈粥樣硬化。凝血酶同時促使纖維蛋白原轉換成纖維蛋白,經聚合橫向連結後,能安定所形成的血小板簇。血小板凝集分為花生四烯酸依賴型與非依賴型兩種,故抗凝藥亦分成二種,前者計有環氧化酶抑制劑、TXA₂合成酶抑制劑、TXA₂拮抗劑、PGI₂活化劑等;後者包括cAMP PDE抑制劑及腺苷酸磷酸二酯酶活化劑等。本文回顧近十年來,有關於cAMP PDE、TXA₂合成酶抑制劑,及其合併抑制劑之文獻,並對其化學結構與活性作系統性介紹,以提供從事心血管藥物研究之參考。 |
英文摘要 | Platelet activation is a complex phenomenon, which causes platelet aggregation and plays an important role in occlusive thrombus formation at the site of adhesion and downstream after embolization. Both are implicated as the early events in the genesis of angina, myocardial infarction and stroke. Thrombin, formed in the course of coagulation cascade, initiates platelet activation and subsequently induces platelet aggregation and release of ADP from various storage granules of platelets. Thrombin also promotes the conversion of fibrinogen to fibrin, which polymerizes, cross-linked and stabilizes the platelet aggregation. ADP released from granules can also activate platelets, leading to activation of additional platelets. Platelet aggregation can be occurred as arachidonic acid (AA)-dependent and AA-independent mechanisms, and compounds possessing anti-aggregating activity are categorized accordingly. A general rule appears to be that drugs which cause an increase in intracellular cAMP inhibit platelet aggregation whereas agents resulting in a reduction in cAMP levels accelerate platelet aggregation. This review article will focus on inhibitors of platelet cAMP phosphodiesterase and those of thromboxane A₂ synthase, with emphasis on newer, more potent compounds as potential anti-thrombotic drugs. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。